Davar, D., Ding, F., Saul, M., Sander, C., Tarhini, A. A., Kirkwood, J. M., & Tawbi, H. A. (2017). High-dose interleukin-2 (HD IL-2) for advanced melanoma: A single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer.
Styl ChicagoDavar, Diwakar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood, a Hussein A. Tawbi. "High-dose Interleukin-2 (HD IL-2) for Advanced Melanoma: A Single Center Experience From the University of Pittsburgh Cancer Institute." J Immunother Cancer 2017.
Citace podle MLADavar, Diwakar, et al. "High-dose Interleukin-2 (HD IL-2) for Advanced Melanoma: A Single Center Experience From the University of Pittsburgh Cancer Institute." J Immunother Cancer 2017.